Abstract
Chelsea Pinnix (MD Anderson Cancer Center, Houston, TX, USA) presented the results of a single-arm, phase 2 trial of response-adapted radiotherapy in patients with indolent B-cell lymphoma. 50 patients with various types of lymphoma (including mucosa-associated lymphoid tissue lymphoma, follicular lymphoma, and low-grade B-cell lymphoma) were enrolled and received ultra-low-dose radiotherapy of 4 Gy in two fractions and were assessed for response every 3 months. Patients with a complete response to radiotherapy then underwent observation alone, whereas those with persistent lymphoma received an additional 20 Gy radiotherapy in ten fractions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
